M&A Deal Summary |
|
---|---|
Date | 2023-10-09 |
Target | Applied StemCell |
Sector | Life Science |
Buyer(s) | QHP Capital |
Sellers(s) | Hermed Capital |
Deal Type | Secondary Buyout |
Advisor(s) | Baird (Financial) |
SEARCH BY
Try For Free 7-Day Free Trial
QHP Capital is a private equity firm focused on healthcare businesses in the middle-market. Specific areas of interest include tech-enabled life sciences and pharma service companies. The Firm seeks to partner with management teams in founder or family-owned companies, and invests in buyouts and other transaction types. QHP Capital was founded in 2022 and is headquartered in Raleigh, North Carolina.
DEAL STATS | # |
---|---|
Overall | 11 of 11 |
Sector (Life Science) | 5 of 5 |
Type (Secondary Buyout) | 3 of 3 |
State (California) | 1 of 1 |
Country (United States) | 11 of 11 |
Year (2023) | 2 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-01-10 |
COPILOT
Maitland, Florida, United States COPILOT is a digital-first patient-centric reimbursement hub services platform intended to support the relationship between patients, healthcare providers and pharmaceutical and device manufacturers. COPILOT was founded in 2010 and is based in Maitland, Florida. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2024-06-12 |
Pro-ficiency
Raleigh, North Carolina, United States Pro-ficiency is an eLearning provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training, and compliance monitoring tools, and real-time data & predictive analytics. Pro-ficiency was founded in 2014 and is based in Raleigh, North Carolina. |
Sell | $100M |
Hermed Capital is a private investment firm focused on the healthcare sector. Specific areas of interest include pharmaceuticals, medical devices & diagnostics, and medical services. Hermed Capital was formed in 2015 and is headquartered in Shanghai
DEAL STATS | # |
---|---|
Overall | 3 of 3 |
Sector (Life Science) | 3 of 3 |
Type (Secondary Buyout) | 1 of 1 |
State (California) | 2 of 2 |
Country (United States) | 2 of 2 |
Year (2023) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2022-04-12 |
Hinova Pharmaceuticals
Chengdu, China Hinova Pharmaceuticals engages in the development and production of drugs in the therapeutic areas of tumors and metabolic diseases. It develops drugs based on technology platforms, such as deuterium and PROTAC. Hinova Pharmaceuticals was founded in 2013 and is based in Chengdu, China. |
Sell | - |